Pharmacogenetics and Oxcarbazepine in Children and Adolescents: Beyond HLA-B*15:02.

ABSTRACT: Background: Oxcarbazepine is thought to be better-tolerated and less susceptible to drug-drug interactions than its predecessor, carbamazepine. Genetic testing for HLA-B*15:02 is recommended in specific populations to identify those at high risk of severe hypersensitivity reactions; however, other pharmacologic and pharmacogenetic factors that can impact drug disposition may be involved. Methods: We present a case of an 8-year-old boy treated with oxcarbazepine who developed drug reaction with eosinophilia and systemic symptoms (DRESS) with Stevens-Johnsons syndrome overlap and was negative for HLA-B*15:02. We review the extant literature related to oxcarbazepine disposition, and potential pharmacogenetic variants in aldoketoreductase 1C (AKR1C<

SUBMITTER: Stancil SL 

PROVIDER: S-EPMC10880270 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature